- Q4 2024 delivered solid demand with nearly 5% constant-currency revenue growth, marking the 12th consecutive quarter of mid-single-digit or better CC growth for Zimmer Biomet. The company exited 2024 at pre-ERP shipping levels, consistent with its stated plan to recover from ERP-related disruptions and maintain financial trajectory. 4Q metrics reflect resilient demand in hips, knees and the higher-growth S.E.T. segment, aided by ongoing portfolio launches and pricing benefits.
- For 2025, the company provides a CC revenue growth target of 3% to 5% and adjusted EPS guidance of $8.15 to $8.35, excluding the Paragon 28 acquisition. Management views 2025 as a year of margin and cash-flow efficiency, with stronger second-half performance driven by new product uptake, ongoing OpEx investments, and ERP-related base effects. Paragon 28 is expected to be accretive to revenue growth post-close (targeted for H1 2025) and to expand Zimmer Biomet’s leadership in foot & ankle within ASC and international channels.
- The strategic plan emphasizes four core priorities (people and culture, operational excellence, innovation/diversification, and a strong M&A framework). Management highlighted a robust product pipeline (e.g., Z1 Triple Tapered Stem, HAMMR, Oxford Partial Cementless Knee, Persona IQ improvements, OsseoFit Shoulder, ROSA Shoulder, and expanded ROSA applications) and a push into ambulatory surgery centers (ASC) with cross-selling opportunities from Paragon 28 across six categories (foot/ankle, forefoot fracture, total ankle, etc.). The company signaled a disciplined balance-sheet posture with >$1B free cash flow in 2024 and expect $1.1–$1.2B in 2025, while maintaining investment-grade credit metrics.